Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Chuikyo Payer Rep Calls for Cost-Effectiveness Assessment of Drugs Used Together with Medical Devices
November 12, 2020
- Japan’s 1st Therapeutic App OK’ed for Health Coverage, Due for Release on Dec. 1
November 12, 2020
- LDP Lawmakers Leery of Off-Year Drug Re-Pricing to Meet on Nov. 26
November 11, 2020
- PM Suga Vows Transparency in COVID-19 Vaccine Review as Immunization Bill Enters Diet Deliberations
November 11, 2020
- Oral Semaglutide, Gilead JAK Inhibitor, Takeda’s PARP Med OK’ed for Listing on Nov. 18
November 11, 2020
- MHLW Says to Publish PAFSC Minutes for COVID-19 Vaccines in 3 Weeks, but Opposition Parties Unimpressed
November 10, 2020
- Public-Private Confab Set for November 16; Pro-Innovation Measures Up for Discussion
November 10, 2020
- Japan to Set New Technical Fee for CureApp’s Quit Smoking App
November 10, 2020
- MHLW Unveils Draft Ordinance for Electronic Distribution of Package Inserts; Use of GS1 Codes Expected
November 10, 2020
- Swiftly Disclose PAFSC Minutes for COVID-19 Vaccines: Opposition Parties
November 9, 2020
- MHLW to Appropriately Handle FY2021 Off-Year Re-Pricing Debate: Minister
November 9, 2020
- MHLW Won’t Exclude Software Programs from Conditional Approval Coverage: Official
November 6, 2020
- Bill to Amend Immunization Act to Enter Lower House Deliberations on November 10
November 6, 2020
- Package Insert Revisions Ordered for Opdivo, Copaxone
November 6, 2020
- Japan Trade Groups Renew Call for Cautious Discussions on Off-Year Re-Pricing: LDP Policy Confab
November 5, 2020
- LDP’s Fiscal Consolidation Panel Calls for Full Implementation of Off-Year Re-Pricing: Interim Report
November 5, 2020
- Ryukaikon Confab Finally Set for November 24; Can Japan Improve Drug Distribution Environment Again?
November 4, 2020
- Working Group Agrees to Designate 10-20 “Stable Supply Medicines” as Top Priority Drugs
November 4, 2020
- Health Minister Stresses Importance of Japan-Made Vaccines Too
November 4, 2020
- Sakigake-Designated HAE Med Berotralstat, AZ’s Acalabrutinib Clear PAFSC Review
November 2, 2020
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…